Skip to main content

REVIEW article

Front. Cell Dev. Biol.
Sec. Cancer Cell Biology
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1514636
This article is part of the Research Topic Host-Microbiota Interactions in Gastrointestinal Diseases and Cancer: Molecular Mechanisms and Therapeutic Opportunities View all articles

Gut Microbiota Therapy in Gastrointestinal Diseases

Provisionally accepted
Hanif Ullah Hanif Ullah 1*Safia Arbab Safia Arbab 2Saira Bibi Saira Bibi 3Chengting Chang Chengting Chang 1Nehaz Muhammad Nehaz Muhammad 4Sajid Ur Rahman Sajid Ur Rahman 5Suleman Suleman Suleman Suleman 6Irfan Ullah Irfan Ullah 3Inam Ul Hassan Inam Ul Hassan 3Yali Tian Yali Tian 1Ka Li Ka Li 1*
  • 1 West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
  • 2 Lanzhou Institute of Husbandry and Pharmaceutical Sciences, Chinese Academy of Agricultural Sciences, Lanzhou, Gansu Province, China
  • 3 Hazara University, Dhodial, Khyber Pakhtunkhwa, Pakistan
  • 4 Hebei normal university, Hebei, China
  • 5 Southern University of Science and Technology, Shenzhen, Guangdong Province, China
  • 6 Government Post Graduate College Dargai, Malakand, Khyber Pakhtunkhwa, Pakistan

The final, formatted version of the article will be published soon.

    The human gut microbiota, consisting of trillions of microorganisms, plays a crucial role in gastrointestinal (GI) health and disease. Dysbiosis, an imbalance in microbial composition, has been linked to a range of GI disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), celiac disease, and colorectal cancer. These conditions are influenced by the interactions between the gut microbiota, the host immune system, and the gut-brain axis.Recent research has highlighted the potential for microbiome-based therapeutic strategies, such as probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary modifications, to restore microbial balance and alleviate disease symptoms. This review examines the role of gut microbiota in the pathogenesis of common gastrointestinal diseases and explores emerging therapeutic approaches aimed at modulating the microbiome. We discuss the scientific foundations of these interventions, their clinical effectiveness, and the challenges in their implementation. The review underscores the therapeutic potential of microbiome-targeted treatments as a novel approach to managing GI disorders, offering personalized and alternative options to conventional therapies. As research in this field continues to evolve, microbiomebased interventions hold promise for improving the treatment and prevention of gastrointestinal diseases.

    Keywords: Gut Microbiota, Gastrointestinal Diseases, Cancer, therapy, dysbiosis Abbreviations: GI, gastrointestinal, IBD, inflammatory bowel disease, FMT, fecal microbiota transplantation, GBA, gut-brain axis

    Received: 21 Oct 2024; Accepted: 03 Feb 2025.

    Copyright: © 2025 Ullah, Arbab, Bibi, Chang, Muhammad, Rahman, Suleman, Ullah, Hassan, Tian and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Hanif Ullah, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
    Ka Li, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.